logo
  Join        Login             Stock Quote

Sucampo (SCMP) Receives FDA Approval Of Snda For Rescula Glaucoma Drops

 December 12, 2012 07:45 AM
 


(By Balaseshan) Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) said it has received U.S. regulatory approval of a supplemental New Drug Application (sNDA) for Rescula (unoprostone isopropyl) to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Sucampo intends to commercialize Rescula in the first quarter of 2013. Open-angle glaucoma is the most common form of glaucoma.

According to the approved product labeling, Rescula may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure. Rescula is a BK (Big Potassium) channel activator, which is different from other IOP lowering agents.

[Related -Top Insider Purchases: ACAD, FCX, CLMS, EPZM, GHDX, SCMP]

Unoprostone isopropyl is a member of Sucampo's family of prostones and is a synthetic docosanoid. Unoprostone isopropyl may have a local effect on BK (Big Potassium) channels in the eye.

BK channels are expressed in contractile tissues like the trabecular meshwork. Rescula may reduce elevated intraocular pressure (IOP) by increasing the outflow of aqueous humor through the trabecular meshwork.

Rescula was originally approved by the FDA in 2000 for the lowering of IOP in open-angle glaucoma and ocular hypertension in patients who are intolerant of or insufficiently responsive to other IOP lowering medications.

In April 2009, Sucampo acquired the commercialization rights to Rescula for the United States and Canada from R-Tech Ueno Ltd. (RTU).

SCMP closed Tuesday's regular session up 6.65% at $4.97. The stock has been trading between $3.78 and $8.50 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.